Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK)
HKD 16.62
(-0.36%)
HKD 16.62
(-0.36%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 75.51 Billion CNY | 6.68% |
| 2022 | 70.78 Billion CNY | 2.57% |
| 2021 | 69.01 Billion CNY | 11.9% |
| 2020 | 61.67 Billion CNY | -5.05% |
| 2019 | 64.95 Billion CNY | 53.79% |
| 2018 | 42.23 Billion CNY | 101.55% |
| 2017 | 20.95 Billion CNY | 4.58% |
| 2016 | 20.03 Billion CNY | 4.76% |
| 2015 | 19.12 Billion CNY | 1.73% |
| 2014 | 18.79 Billion CNY | 6.77% |
| 2013 | 17.6 Billion CNY | 113.98% |
| 2012 | 8.22 Billion CNY | 51.28% |
| 2011 | 5.43 Billion CNY | 21.26% |
| 2010 | 4.48 Billion CNY | 15.56% |
| 2009 | 3.88 Billion CNY | 10.05% |
| 2008 | 3.52 Billion CNY | -71.37% |
| 2007 | 12.32 Billion CNY | 20.31% |
| 2006 | 10.24 Billion CNY | 13.46% |
| 2005 | 9.02 Billion CNY | 17.1% |
| 2004 | 7.7 Billion CNY | 10.56% |
| 2003 | 6.97 Billion CNY | 17.3% |
| 2002 | 5.94 Billion CNY | 11.43% |
| 2001 | 5.33 Billion CNY | 26.31% |
| 2000 | 4.22 Billion CNY | 22.24% |
| 1999 | 3.45 Billion CNY | 2.09% |
| 1998 | 3.38 Billion CNY | 10.14% |
| 1997 | 3.07 Billion CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 18.01 Billion CNY | -0.44% |
| 2024 Q2 | 18.09 Billion CNY | -21.13% |
| 2024 Q1 | 22.94 Billion CNY | 32.4% |
| 2023 FY | 75.51 Billion CNY | 6.68% |
| 2023 Q2 | 18.34 Billion CNY | -15.2% |
| 2023 Q3 | 18.21 Billion CNY | -0.7% |
| 2023 Q1 | 21.62 Billion CNY | 35.33% |
| 2023 Q4 | 17.33 Billion CNY | -4.85% |
| 2022 Q4 | 15.98 Billion CNY | -9.12% |
| 2022 Q2 | 16.68 Billion CNY | -18.78% |
| 2022 Q1 | 20.53 Billion CNY | 32.72% |
| 2022 FY | 70.78 Billion CNY | 2.57% |
| 2022 Q3 | 17.58 Billion CNY | 5.42% |
| 2021 Q2 | 16.08 Billion CNY | -19.77% |
| 2021 Q1 | 20.04 Billion CNY | 35.55% |
| 2021 Q4 | 15.47 Billion CNY | -11.12% |
| 2021 Q3 | 17.41 Billion CNY | 8.26% |
| 2021 FY | 69.01 Billion CNY | 11.9% |
| 2020 FY | 61.67 Billion CNY | -5.05% |
| 2020 Q3 | 16.41 Billion CNY | 21.73% |
| 2020 Q4 | 14.78 Billion CNY | -9.9% |
| 2020 Q1 | 16.98 Billion CNY | 14.07% |
| 2020 Q2 | 13.48 Billion CNY | -20.6% |
| 2019 Q2 | 15.28 Billion CNY | -15.34% |
| 2019 FY | 64.95 Billion CNY | 53.79% |
| 2019 Q1 | 18.05 Billion CNY | 46.1% |
| 2019 Q3 | 16.72 Billion CNY | 9.39% |
| 2019 Q4 | 14.88 Billion CNY | -10.96% |
| 2018 Q2 | 7.93 Billion CNY | 14.79% |
| 2018 Q4 | 12.35 Billion CNY | -17.81% |
| 2018 FY | 42.23 Billion CNY | 101.55% |
| 2018 Q1 | 6.9 Billion CNY | 38.54% |
| 2018 Q3 | 15.03 Billion CNY | 89.59% |
| 2017 Q3 | 4.85 Billion CNY | -16.75% |
| 2017 FY | 20.95 Billion CNY | 4.58% |
| 2017 Q4 | 4.98 Billion CNY | 2.8% |
| 2017 Q2 | 5.82 Billion CNY | 10.2% |
| 2017 Q1 | 5.28 Billion CNY | 17.72% |
| 2016 FY | 20.03 Billion CNY | 4.76% |
| 2016 Q1 | 5.05 Billion CNY | 24.6% |
| 2016 Q2 | 5.8 Billion CNY | 14.96% |
| 2016 Q3 | 4.68 Billion CNY | -19.29% |
| 2016 Q4 | 4.49 Billion CNY | -4.15% |
| 2015 Q2 | 5.74 Billion CNY | 21.39% |
| 2015 FY | 19.12 Billion CNY | 1.73% |
| 2015 Q1 | 4.73 Billion CNY | 13.58% |
| 2015 Q4 | 4.05 Billion CNY | -11.71% |
| 2015 Q3 | 4.59 Billion CNY | -20.04% |
| 2014 Q1 | 4.67 Billion CNY | 6.18% |
| 2014 Q3 | 4.61 Billion CNY | -13.65% |
| 2014 Q2 | 5.34 Billion CNY | 14.31% |
| 2014 FY | 18.79 Billion CNY | 6.77% |
| 2014 Q4 | 4.16 Billion CNY | -9.76% |
| 2013 FY | 17.6 Billion CNY | 113.98% |
| 2013 Q1 | 2.97 Billion CNY | 7.92% |
| 2013 Q2 | 6.1 Billion CNY | 105.25% |
| 2013 Q4 | 4.4 Billion CNY | 6.56% |
| 2013 Q3 | 4.13 Billion CNY | -32.26% |
| 2012 Q3 | 1.97 Billion CNY | 18.28% |
| 2012 Q1 | 1.82 Billion CNY | 38.66% |
| 2012 FY | 8.22 Billion CNY | 51.28% |
| 2012 Q4 | 2.75 Billion CNY | 39.3% |
| 2012 Q2 | 1.67 Billion CNY | -8.49% |
| 2011 Q2 | 1.44 Billion CNY | 4.58% |
| 2011 Q3 | 1.3 Billion CNY | -9.39% |
| 2011 Q4 | 1.31 Billion CNY | 0.94% |
| 2011 FY | 5.43 Billion CNY | 21.26% |
| 2011 Q1 | 1.37 Billion CNY | 30.88% |
| 2010 Q1 | 1.24 Billion CNY | 26.34% |
| 2010 Q3 | 1.11 Billion CNY | 2.83% |
| 2010 FY | 4.48 Billion CNY | 15.56% |
| 2010 Q4 | 1.05 Billion CNY | -5.37% |
| 2010 Q2 | 1.08 Billion CNY | -12.85% |
| 2009 Q1 | 1.03 Billion CNY | 35.27% |
| 2009 FY | 3.88 Billion CNY | 10.05% |
| 2009 Q4 | 982.05 Million CNY | 2.77% |
| 2009 Q3 | 955.58 Million CNY | 5.17% |
| 2009 Q2 | 908.6 Million CNY | -12.27% |
| 2008 FY | 3.52 Billion CNY | -71.37% |
| 2008 Q4 | 765.62 Million CNY | 16.29% |
| 2008 Q3 | 658.38 Million CNY | -71.33% |
| 2008 Q1 | 2.51 Billion CNY | -21.96% |
| 2008 Q2 | 2.29 Billion CNY | -8.73% |
| 2007 Q3 | 3.08 Billion CNY | 5.39% |
| 2007 FY | 12.32 Billion CNY | 20.31% |
| 2007 Q1 | 3.09 Billion CNY | 28.15% |
| 2007 Q2 | 2.92 Billion CNY | -5.43% |
| 2007 Q4 | 3.22 Billion CNY | 4.61% |
| 2006 Q1 | 2.61 Billion CNY | 23.02% |
| 2006 Q4 | 2.41 Billion CNY | -8.41% |
| 2006 FY | 10.24 Billion CNY | 13.46% |
| 2006 Q3 | 2.63 Billion CNY | 2.25% |
| 2006 Q2 | 2.57 Billion CNY | -1.58% |
| 2005 Q4 | 2.12 Billion CNY | -7.57% |
| 2005 Q3 | 2.3 Billion CNY | 2.4% |
| 2005 Q2 | 2.24 Billion CNY | -4.23% |
| 2005 Q1 | 2.34 Billion CNY | 35.49% |
| 2005 FY | 9.02 Billion CNY | 17.1% |
| 2004 Q3 | 1.98 Billion CNY | 3.63% |
| 2004 Q1 | 2.07 Billion CNY | 28.49% |
| 2004 FY | 7.7 Billion CNY | 10.56% |
| 2004 Q4 | 1.73 Billion CNY | -12.7% |
| 2004 Q2 | 1.91 Billion CNY | -7.71% |
| 2003 Q1 | 1.82 Billion CNY | 34.2% |
| 2003 Q2 | 1.75 Billion CNY | -3.61% |
| 2003 Q3 | 1.77 Billion CNY | 1.33% |
| 2003 FY | 6.97 Billion CNY | 17.3% |
| 2003 Q4 | 1.61 Billion CNY | -9.22% |
| 2002 Q1 | 1.49 Billion CNY | 0.0% |
| 2002 Q4 | 1.35 Billion CNY | -14.4% |
| 2002 Q3 | 1.58 Billion CNY | 4.95% |
| 2002 Q2 | 1.51 Billion CNY | 1.38% |
| 2002 FY | 5.94 Billion CNY | 11.43% |
| 2001 FY | 5.33 Billion CNY | 26.31% |
| 2000 FY | 4.22 Billion CNY | 22.24% |
| 1999 FY | 3.45 Billion CNY | 2.09% |
| 1998 FY | 3.38 Billion CNY | 10.14% |
| 1997 FY | 3.07 Billion CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -29038.751% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | -617.173% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -127679.965% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -9533.529% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -7755.624% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -7071.222% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -4325.017% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -9233.179% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -18460.583% |
| SSY Group Limited | 6.46 Billion HKD | -1068.425% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -11546.153% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -5044.809% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 72.072% |